This phase II/III trial is testing a new drug (ADI-PEG 20) in combination with standard chemotherapy for patients with pleural mesothelioma.
This trial is treating patients with mesothelioma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Commercial Sponsor
Polaris Group
Summary
Eligible patients will be randomised to receive 36 mg/m2 of weekly ADI-PEG 20 or a placebo, in combination with pemetrexed (500mg/m2) and cisplatin (75mg/m2) which will be administered intravenously every three weeks.
Not Recruiting Hospitals Read More